Acticor Biotech

Acticor Biotech EBITDA per Employee

Delisted

The EBITDA per Employee of Acticor Biotech (ALACT.PA) as of Nov 7, 2026 is -731,250.00 EUR. In the previous year, EBITDA per Employee was -626,458.33 EUR — a change of 16.73% (lower).

EBITDA per Employee

-731,250.00EUR

YoY

16.73%

Last updated:

EBITDA per Employee of Acticor Biotech is 2023 -731,250.00 EUR. EBITDA per Employee of Acticor Biotech was 2022 -626,458.33 EUR. It decreases by 16.73% lower compared to the previous year.

The Acticor Biotech EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2016
23,116.67 EUR
Jan 1, 2017
-50,254.17 EUR
Jan 1, 2018
-44,779.17 EUR
Jan 1, 2019
-194,833.33 EUR
Jan 1, 2020
-311,125.00 EUR
Jan 1, 2021
-491,208.33 EUR
Jan 1, 2022
-626,458.33 EUR
Jan 1, 2023
-731,250.00 EUR
The Acticor Biotech EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-731,250.00EUR+16.73%
-626,458.33EUR+27.53%
-491,208.33EUR+57.88%
-311,125.00EUR+59.69%
-194,833.33EUR+335.10%
-44,779.17EUR-10.89%
-50,254.17EUR-317.39%
23,116.67EUR-154.02%
-42,795.83EUR-138.90%
110,008.33EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Acticor Biotech Stock analysis

What does Acticor Biotech do? Acticor Biotech SA develops antithrombotic agents for acute thrombotic diseases, focusing on acute ischemic strokes and pulmonary embolisms. The company has one product, Glenzocimab, in Phase II clinical development, alongside pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN. It collaborates with partnering companies Ouest Valorisation, Genopole, Medicine, and Inserm for research and development. Acticor Biotech SAS is a clinical stage biopharmaceutical company spun off from INSERM, with 24 full-time employees. The firm generates revenue through its research and development activities, leveraging its partnership with INSERM and other institutions. Glenzocimab, its lead product, is in Phase II trials, indicating potential future licensing agreements or sales. The company's pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN represent additional revenue streams once they progress through clinical development. Acticor Biotech targets the biopharmaceutical sector, specifically focusing on thrombotic disease treatments. Its primary customers are pharmaceutical companies seeking to license or co-develop novel antithrombotic therapies. The company's partnerships with Ouest Valorisation, Genopole, Medicine, and Inserm facilitate its R&D efforts and potential commercialization pathways. Acticor Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acticor Biotech stock

EBITDA per Employee of Acticor Biotech is -731,250.00 EUR in 2023.

EBITDA per Employee of Acticor Biotech changed from -626,458.33 EUR to -731,250.00 EUR, representing a 16.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Acticor Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Acticor Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Acticor Biotech

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Acticor Biotech